- Sunesis Pharmaceuticals (SNSS) opens the 100 mg cohort in its Phase 1b/2 clinical trial evaluating BTK inhibitor vecabrutinib in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell blood cancers.
- Data on the 50 mg group were presented at ASH last month.
- The company expects the target dose will be between 100 mg and 300 mg twice daily.
- Updated data will be presented at a major medical meeting next quarter.
- Previously: Sunesis Pharma down 34% on vecabrutinib data (Dec. 3, 2018)
Sunesis advancing blood cancer candidate vecabrutinib
Recommended For You
More Trending News
About VIRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VIRX | - | - |
Viracta Therapeutics, Inc. |